Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients

NCT02500849 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

HIV

Interventions

GENETIC: SB-728mR-HSPC Infusion 3 days following busulfan conditioning

Sponsor

City of Hope Medical Center

Collaborators

[object Object]
[object Object]